Daeun Shin

Daeun Shin

Auto-generated profile, based on publicly available information

Daeun Shin

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Dementia and Neurocognitive Disorders
Verified
Journal Article
Open access
PDF file
HJHyemin Jang
Hyemin Jang
DSDaeun Shin
Daeun Shin
YKYeshin Kim
Yeshin Kim
KKKo Woon Kim
Ko Woon Kim
JLJuyoun Lee
Juyoun Lee
OGon behalf of the K-ROAD Study Groups
on behalf of the K-ROAD Study Groups
Jang H, et al. Dement Neurocogn Disord. 2024 Oct;23(4):212-223. https://doi.org/10.12779/dnd.2024.23.4.212

7 August 2025 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
HKHeekyoung Kang
Heekyoung Kang
HYHeejin Yoo
Heejin Yoo
JLJungah Lee
Jungah Lee
SYSoyeon Yoon
Soyeon Yoon
HZHenrik Zetterberg
Henrik Zetterberg
TGthe K-ROAD study group
the K-ROAD study group
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ) pathology. Recently, plasma biomarkers, particularly p-tau217, have emerged as promising tools for early diagnosis and risk stratification. In this retrospective study, we evaluated the diagnostic performance of p-tau217 combined with other plasma biomarkers in distinguishing Aβ Positron emission tomography (PET) positivity in cognitively unimpaired (CU) and cognitively impaired (CI) individuals across diverse clinical subgroups. We analyzed 2,497 participants from the Korea-Registries to Overcome dementia and Accelerate Dementia (K-ROAD) cohort, including 636 CU and 1,971 CI individuals. Plasma p-tau217 was measured using both SIngle MOlecule Array (SIMOA) and Meso Scale Discovery (MSD) assays, alongside Aβ42/40, Glial fibrillary acidic protein (GFAP), and Neurofilament light chain (NfL). We assessed the diagnostic performance of biomarker combinations for Aβ PET positivity through the area under the receiver operating characteristic curve (AUC), Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC), and performed subgroup analyses based on age, sex, body mass index (BMI), and Apolipoprotein E (APOE) ε4 status. To assess applicability, we stratified the cohort by recruitment site into a development set (Samsung Medical Center, n = 1,545) and a validation set (other centers, n = 952). In CU individuals from the development cohort, the combination of p-tau217 and Aβ42/40 significantly improved diagnostic accuracy (AUC: ALZpath 0.937 vs. 0.905, MSD 0.901 vs. 0.861; p < 0.05, DeLong test; 95% CIs) and model fit (AIC /BIC, p < 0.001) compared to p-tau217 alone. In contrast, in CI individuals, the combination provided only modest improvements in model fit without significantly enhancing AUC. GFAP and NfL did not contribute significantly to amyloid detection in either group. These findings were successfully validated in an independent cohort from other centers. Subgroup analyses in CU individuals showed the greatest improvements in older adults, females, and APOE4 non-carriers, regardless of obesity status. In CI individuals, the combination had no significant impact on AUC except in males, where a small but significant increase was observed (p = 0.002). Combining p-tau217 with Aβ42/40 enhances amyloid detection in CU individuals, improving both diagnostic accuracy and model fit, whereas its impact in CI individuals is limited. These results highlight the potential of plasma biomarker combinations for refining early AD diagnostics and individualized risk assessment.

1 January 2025 in Dementia and Neurocognitive Disorders
Verified
Journal Article
Open access
PDF file
HKHeekyoung Kang
Heekyoung Kang
SWSook-Young Woo
Sook-Young Woo
DSDaeun Shin
Daeun Shin
SYSohyun Yim
Sohyun Yim
ELEun Hye Lee
Eun Hye Lee
OGon behalf of the K-ROAD Study Groups
on behalf of the K-ROAD Study Groups
Kang H, et al. Dement Neurocogn Disord. 2025 Apr;24(2):91-101. https://doi.org/10.12779/dnd.2025.24.2.91

22 June 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
YGYuna Gu
Yuna Gu
JYJihwan Yun
Jihwan Yun
AMAlexis Moscoso
Alexis Moscoso
MSMichael Schöll
Michael Schöll
DSDaeun Shin
Daeun Shin
AGADNI and K‐ROAD study groups
ADNI and K‐ROAD study groups
INTRODUCTION: We compared visual assessments and quantification methods for tau positron emission tomography (PET) staging and evaluated plasma biomarkers and cognitive trajectories across amyloid and tau (AT) staging.METHODS: Tau PET scans from 289 Korea‐Registries to Overcome Dementia and Accelerate Dementia Research (K‐ROAD) participants were analyzed visually and quantitatively, with validation in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (n = 870). Plasma biomarkers and cognitive measures were evaluated across AT stages.RESULTS: FreeSurfer without partial volume correction (PVC) achieved the highest area under the curve (AUC) for tau positivity (0.918), based on visual interpretation. The temporal meta‐region excelled in moderate tau staging (AUC = 0.856), while the temporoparietal region performed best for advanced staging (AUC = 0.828). Quantification methods detected phosphorylated tau217 changes during intermediate transitions (e.g., A+/T− to A+/Tmod+) more effectively. Plasma biomarkers and cognitive measures progressively changed across AT stages, with consistent results in K‐ROAD and ADNI cohorts.DISCUSSION: The complementary strengths of visual and quantification methods enhance tau PET staging by effectively capturing biomarker changes and cognitive trajectories.Highlights: Quantification partially outperformed visual assessments in detecting early tau burdens. Meta‐temporal and temporoparietal regions of interest excelled in early and late tau staging. Quantification methods correlated with plasma phosphorylated tau217 and cognitive decline. Findings were validated across two independent cohorts (Korea‐Registries to Overcome Dementia and Accelerate Dementia Research and Alzheimer's Disease Neuroimaging Initiative). The study highlights the complementary roles of visual and quantification methods.

1 September 2025 in Clinical Nuclear Medicine
Verified
Journal Article
Open access
SYSohyun Yim
Sohyun Yim
YGYuna Gu
Yuna Gu
HKHeekyung Kang
Heekyung Kang
DSDaeun Shin
Daeun Shin
HJHyemin Jang
Hyemin Jang
OGon behalf of the K-ROAD study groups
on behalf of the K-ROAD study groups
Background: Alzheimer disease (AD) is characterized by amyloid-β plaques (A), tau tangles (T), and neurodegeneration (N), collectively defining the ATN framework. While imaging biomarkers are well-established, the prognostic value of plasma biomarkers in predicting cognitive decline remains underexplored. This study compares plasma and imaging A/T/N biomarkers in predicting cognitive decline and evaluate the impact of combining biomarkers across modalities. Patients and Methods: We conducted a longitudinal study using K-ROAD cohort participants who underwent at least 2 cognitive assessments. All participants had plasma biomarker testing (Aβ ratio, p-tau181, p-tau231, p-tau217, NfL), and a subset with imaging biomarker assessments (Aβ PET, tau PET, structural MRI) formed an imaging subcohort. Multiple linear regression models identified the most predictive markers within each modality and evaluated the effect of combining A/T/N biomarkers. Results: Among 1,614 plasma cohort and 130 imaging subcohort participants, tau markers demonstrated the strongest predictive value. p-tau217 MSD outperforming other plasma biomarkers, and the neo-temporal ROI showing the highest predictive power among imaging biomarkers. In plasma-based model, adding neurodegeneration markers to combination of amyloid and tau biomarkers improved the performance. In imaging-based models, same strategy decreased the performance, suggesting that combinations of amyloid and tau PET captures the most relevant prognostic information. Conclusions: Imaging biomarkers, particularly tau PET, show superior prognostic accuracy compared with plasma biomarkers, whereas plasma biomarkers offer advantages in combination models through neurodegeneration markers. These findings underscore the complementary roles of plasma and imaging biomarkers and emphasize the need for tailored strategies for prognostic modeling in AD.

31 May 2021 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
HRHo-Sung Ryu
Ho-Sung Ryu
MCMinsub Cho
Minsub Cho
DSDaeun Shin
Daeun Shin
YHYang-Ha Hwang
Yang-Ha Hwang